Figures (5)  Tables (1)

    • Figure 1. 

      Typical photomicrographs of multiple immunofluorescence staining: (a) CD8+ (white); (b) CD56+ (purple); (c) CD68+ (green) and HLA-DR (red); and (d) Reconstructed image after removal of autofluorescence and local enlargement. The lower right panel of (d) is a 4× magnified image of the selected region.

    • Figure 2. 

      The density of immune infiltrating cells in the tumor parenchyma and OS in patients receiving adjuvant chemotherapy. (a) M1 cells; (b) M2 cells; (c) CD56bright cells; (d) CD56dim cells; (e) CD8+ T-cells.

    • Figure 3. 

      The density of immune infiltrating cells in the tumor stroma and OS in patients receiving adjuvant chemotherapy. (a) M1 cells; (b) M2 cells; (c) CD56bright cells; (d) CD56dim cells; and (e) CD8+ T-cells.

    • Figure 4. 

      The impact of ACT on OS in patients with high-density immune infiltrating cells in the tumor parenchyma. (a) M1 cells; (b) M2 cells; (c) CD56bright cells; (d) CD56dim cells; and (e) CD8+ T-cells.

    • Figure 5. 

      The impact of adjuvant chemotherapy on overall survival in patients with high-density immune infiltrating cells in the tumor stroma. (a) M1 cells; (b) M2 cells; (c) CD56bright cells; (d) CD56dim cells; and (e) CD8+ T cells.

    • Variable Group Adjuvant chemotherapy p-Value
      No Yes
      Age (years) < 65 8 (36.4) 10 (40.0) 0.798
      ≥ 65 14 (63.6) 15 (60.0)
      Sex Female 3 (13.6) 7 (28.0) 0.230
      Male 19 (86.4) 18 (72.0)
      Histological grade I/II 5 (22.7) 5 (20.0) 0.820
      III 17 (77.3) 20 (80.0)
      Stage II 7 (31.8) 6 (24.0) 0.550
      III 15 (68.2) 19 (76.0)

      Table 1. 

      Patient characteristics.